Skip to main content
PMC home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2006 Sep;21(2):42–48. doi: 10.1007/BF02912910

The use of lysosomal enzymuria in the early detection and monitoring of the progression of diabetic nephropathy

Donatien Gatsing 1,✉, Ibrahim Hassan Garba 2, Godwin I Adoga 3
PMCID: PMC3453975  PMID: 23105612

Abstract

Recent acquisitions on the early detection and monitoring of the progression of diabetic complications (nephropathy) using the techniques of enzymology (lysosomal enzymes) are reviewed. it appears that the kidney is the principal source of urinary lysosomal enzymes. Urinary samples for lysosomal enzyme determination can be either 24-hour or spot-collection. The use of synthetic substrates (4-methylumbelliferyl substrates) provides an easy, inexpensive, sensitive and highly reproducible method of lysosomal enzyme assay. It is recommended that more than one enzyme be assayed in the process. The use of fractional enzyme excretion (FEE) ratios is further recommended. The urinary lysosomal glycosidases investigated and found to be of particular diagnostic value in the early detection of diabetic nephropathy include N-acetyl-β-D-glucosaminidase (β-hexosaminidase, NAG), β-glucuronidase and β-galactosidase, with NAG being the most useful indicator. Urinary NAG can be used in monitoring the progression of diabetic nephropathy. The fluorimetric assay of lysosomal glycosidases is particuarly recommended in developing countries since it is simple, sensitive and inexpensive.

Key words: Lysosomal enzymuria, diabetic nephropathy, N-acetyl-β-D-glucosaminidase

Full Text

The Full Text of this article is available as a PDF (85.0 KB).

References

  • 1.Cheesbrough M. Medical Laboratory Manual for Tropical Countries. 2nd edn. Cambridge: Educational Low-Price Books Scheme; 1991. pp. 527–545. [Google Scholar]
  • 2.Howards B.V. Lipoprotein metabolism in diabetes mellitus. J. Lipid Res. 1987;28:613–623. [PubMed] [Google Scholar]
  • 3.Adoga, G.I. and Glew, R.H. (1995) Lysosomal enzymes in the diagnosis and management of complications in diabetes mellitus. International Diabetes Digest, 12–15.
  • 4.Dalla V.M., Saller A., Bortoloso E., Mauer M., Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab. 2000;26(4):8–14. [PubMed] [Google Scholar]
  • 5.Moriya T., Tanaka K., Moriya R. Glomerular structural changes and structural-functional relationships at early stage of diabetic nephropathy in Japanese type 2 diabetic patients. Med. Electron Microsc. 2000;33(3):115–22. doi: 10.1007/s007950000010. [DOI] [PubMed] [Google Scholar]
  • 6.Tarchini R., Bottini E., Botti P., Marseglia C.D., Talassi E., Baraldi O., Lambertini D., Gaetti L., Bellomi A. Type 2 diabetic nephropathy: evolution and prevention. G. Ital. Nefrol. 2005;22(31):15–19. [PubMed] [Google Scholar]
  • 7.Al-Hermi B.E., Al-Abbasi A.M., Rajab M.H., Al-Jenaidi F.A., Al-Ekri Z.E. Diabetic nephropathy in children with type 1 diabetes mellitus in Bahrain. Saudi Med J. 2005;26(2):294–297. [PubMed] [Google Scholar]
  • 8.Garba, I.H., Ubom, G., Gatsing, D. and Awwal, M. (2005) Acid phosphatase activity as a potential prognostic marker in patients with benign prostate hyperplasia (BPH) The Internet Journal of Surgery 6(1).
  • 9.Garba, I.H., Gatsing, D., Awwal and Gadzama, J. (2005) Alanine and aspartate transaminases in the serum of acute appendicitis patients before and after surgery. The Internet Journal of Gastroenterology 4(1).
  • 10.Gatsing D., Adoga G.I. Lysosomal enzymuria in the diagnosis and monitoring of diabetic nephropathy. L'Eurobiologiste Tome. 2004;XXXV(No 271):1–4. [Google Scholar]
  • 11.Gorog O., Pearson J.D. Sialic acid moieties on surface glycoproteins protect endothelial cells from prolytic damage. J. Pathol. 1985;146:205–212. doi: 10.1002/path.1711460307. [DOI] [PubMed] [Google Scholar]
  • 12.Yazzie D., Adoga G.I., Okolo A., Szlachetka R., Fry D., Glew R.H. Decreased urinary excretion of β-glucuronidase in sickle cell anemia in Nigeria. Renal Failure. 1995;17(1):57–64. doi: 10.3109/08860229509036376. [DOI] [PubMed] [Google Scholar]
  • 13.Lombardo A., Caimi L., Marchesini S., Goi G.C., Tettamanti G. Enzymes of lysosomal origin in human plasma and serum: assay conditions and parameters influencing the assay. Clin. Chim. Acta. 1980;108:337–346. doi: 10.1016/0009-8981(80)90339-3. [DOI] [PubMed] [Google Scholar]
  • 14.Maruhn D. Preparation of urine for enzyme determinations by gel filtration, in diagnostic significance of enzymes and proteins in urine. Berne: Hans-Huber; 1979. pp. 22–22. [PubMed] [Google Scholar]
  • 15.Price R.G. Urinary enzymes, nephrotoxicity and renal disease. Toxicology. 1982;23:99–134. doi: 10.1016/0300-483X(82)90092-0. [DOI] [PubMed] [Google Scholar]
  • 16.Jagt D.J., Steinberg B.R., Glew R.H. Comparison of urinary excretion of four lysosomal hydrolases in healthy elderly and young adults. Clin. Chim. Acta. 1992;210:47–54. doi: 10.1016/0009-8981(92)90044-Q. [DOI] [PubMed] [Google Scholar]
  • 17.Maruhn D., Strozyk K., Gielow L., Bokc K.D. Diurnal variations of urinary enzyme excretion. Clin. Chim. Acta. 1977;75:427–433. doi: 10.1016/0009-8981(77)90362-X. [DOI] [PubMed] [Google Scholar]
  • 18.Stroo W.E., Hook J.B. Enzymes of renal origin in urine as indicators of nephrotoxicity. Toxicol. Appl. Pharmacol. 1977;39:423–434. doi: 10.1016/0041-008X(77)90135-1. [DOI] [PubMed] [Google Scholar]
  • 19.Dingle, J.T. (1972), Lysosomes: A Laboratory hand book. North-Holland Publishing Company, 188 p.
  • 20.Balami D., Adoga G.I., Okpe S.E. Changes in lysosomal enzymes activities in paediatric patients in Jos, Nigeria. West African Journal of Biological Sciences. 1998;7:156–160. [Google Scholar]
  • 21.Gatsing D., Adoga G.I., Garba I.H., Obekpa P., Towa Y.K. The use of acid phosphatase in the monitoring of laryngeal carcinoma. L'Eurobiologiste Tome. 2000;XXXIV(No 248–249):31–34. [Google Scholar]
  • 22.Gatsing D., Adoga G.I., Obekpa P. b-Glucuronidase, b-galactosidase, and acid phosphatase activities in liposarcoma patients before and after surgical intervention. L'Eurobiologiste Tome. 2002;XXXV(No 259):11–14. [Google Scholar]
  • 23.Gatsing D., Adoga G.I., Dondji B., Obekpa P. Effect of surgical intervention on levels of β-galactosidase and b-glucuronidase in patients with prostatic carcinoma. Ann. Fac. Sci. Ydé I. 2003;35(2):29–32. [Google Scholar]
  • 24.Berty R.M., Adler S., Basu A., Glew R.H. Effect of acid-base changes on urinary hydrolases in Fabry's disease after renal transplantation. J. Lab. Clin. Med. 1990;115:696–703. [PubMed] [Google Scholar]
  • 25.Kunin C.M., Chesney R.W., Craig W.A., England A.C., Angelis C. Enzymuria as a marker of renal injury and disease: Studies of N-acetyl-β-D-glucosaminidase in the general population and in patients with renal disease. Paediatrics. 1978;62:751–760. [PubMed] [Google Scholar]
  • 26.Tombach B, Bremer C., Reimer P., Kisters K., Schaefer R.M., Geens V., Heindel W. Contrast mediarenal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study 1. Radiology. 2001;218:651–657. doi: 10.1148/radiology.218.3.r01mr12651. [DOI] [PubMed] [Google Scholar]
  • 27.Obatomi D.K., Plummer D.T. Amelioration of gentamicin nephrotoxicity by cefuroxime. Med. Sci. Res. 1990;18:593–594. [Google Scholar]
  • 28.Kelly L., Woodard S.H. Alternations in the activities of lysosomal glycosidases in human diabetic. Medical Science Research. 1988;16:491–496. [Google Scholar]
  • 29.Salema M.A.K., El-Habashya S.A., Saeidb O.M., El-Tawila M.M.K., Tawfikc P.H. Urinary excretion of n-acetyl—d-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus. Pediatric Diabetes. 2002;3(1):37–37. doi: 10.1034/j.1399-5448.2002.30107.x. [DOI] [PubMed] [Google Scholar]
  • 30.Baggio B., Brianu G., Cicerello E. Urinary glycosaminoglycans, sialic acid and lysosomal enzymes increase in nonalbuminuric diabetic patients. Nephron. 1986;43:187–190. doi: 10.1159/000132319. [DOI] [PubMed] [Google Scholar]
  • 31.Bomback F.M., Nakagawa S., Kumin S., Nitowsky H.M. Altered lysosomal glycohydrolase activities in juvenile diabetes mellitus. Diabetes. 1976;25:420–427. doi: 10.2337/diabetes.25.5.420. [DOI] [PubMed] [Google Scholar]
  • 32.Dedov I.I., Mukhin N.A., Pal'tsev M.A., Delektorskaia L.N., Shestakova M.V. Urinary enzymes as a marker of the preclinical stage of diabetic nephropathy. Ter. Arkh. 1989;61(12):73–76. [PubMed] [Google Scholar]
  • 33.Chouinard S., Viau C., Greselin E. Enzymuria and tubular proteinuria in diabetic rats: a 12-week follow-up study. Ren. Fail. 1992;14(1):41–47. doi: 10.3109/08860229209039115. [DOI] [PubMed] [Google Scholar]
  • 34.Minakami H. Clinical evaluation of N-acetyl-β-D-glucosaminidase on prediction of diabetic nephropathy. Hokkaido Igaku Zasshi. 1992;67(2):234–246. [PubMed] [Google Scholar]
  • 35.Ikenaga H., Suzuki H., Ishii N., Itoh H., Saruta T. Enzymuria in non-insulin-dependent diabetic patients: signs of tubular cell dysfunction. Clin. Sci. 1993;84(4):469–475. doi: 10.1042/cs0840469. [DOI] [PubMed] [Google Scholar]
  • 36.Golov K.G., Varshavskii V.A., Okunev D.I.U., Neverov N.I., Shestakova M.V., Proskurneva F.P. Urinary enzymes in the assessment of the early stage of kidney involvement in psoriasis and diabetes mellitus. Ter. Arkh. 1995;67(10):80–81. [PubMed] [Google Scholar]
  • 37.Maisant A., Sitzmann F.C., Strohlein S. N-acetyl-β-glucosaminidase (β-NAG) in urine: a parameter for early detection of diabetogenic nephropathy in childhood. Padiatr. Padol. 1993;28(3):77–80. [PubMed] [Google Scholar]
  • 38.Nosadini R. Hypertension and renal complications in type 2 diabetes. Semin. Vasc. Med. 2002;2(1):109–119. doi: 10.1055/s-2002-23101. [DOI] [PubMed] [Google Scholar]
  • 39.Groop L., Stenman S., Groop P.H., Makipernaa A., Teppo A.M. The effect of exercise on urinary excretion of different size proteins in patients with insulin-dependent diabetes mellitus. Scand. J. Clin. Lab. Invest. 1990;50:525–532. doi: 10.3109/00365519009089167. [DOI] [PubMed] [Google Scholar]
  • 40.Muirhead, N. (1988). The kidney as an endocrine organ. In: Catto, G.R.D. and Power, D.A. (eds.). Nephrology in clinical practice. Edward Arnold, pp 50–71.
  • 41.Reddi A.S., Jyothirmayi G.N. Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats. Journal of Diabetes Complications. 1993;7(4):233–240. doi: 10.1016/S0002-9610(05)80250-8. [DOI] [PubMed] [Google Scholar]
  • 42.Parving H.H., Tarnow L., Rossing P. Genetics of diabetic nephropathy. J. Am. Soc. Nephrol. 1996;7(12):2509–2517. doi: 10.1681/ASN.V7122509. [DOI] [PubMed] [Google Scholar]
  • 43.Wang P.H., Lau J., Chalmers T.C. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993;341(8856):1306–1309. doi: 10.1016/0140-6736(93)90816-Y. [DOI] [PubMed] [Google Scholar]
  • 44.Dalla V.M., Saller A., Mauer M., Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J. Nephrol. 2001;14(4):51–57. [PubMed] [Google Scholar]
  • 45.Wei P., Lane P.H., Lane J.T., Padanilam B.J., Sansom S.C. Glomerular structural and functional changes in a high-fat diet mouse model of early-stage Type 2 diabetes. Diabetologia. 2004;47(9):1541–1549. doi: 10.1007/s00125-004-1489-1. [DOI] [PubMed] [Google Scholar]
  • 46.Materson B.J., Preston R.A. Prevention of diabetic nephropathy. Hosp. Pract. (Off Ed) 1997;32(2):129–134. doi: 10.1080/21548331.1997.11443426. [DOI] [PubMed] [Google Scholar]
  • 47.Maeda M., Yabuki A., Suzuki S., Matsumoto M., Taniguchi K., Nishinakagawa H. Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse: acute phase of diabetes. Vet. Pathol. 2003;40(2):187–195. doi: 10.1354/vp.40-2-187. [DOI] [PubMed] [Google Scholar]
  • 48.Molnar M., Wittmann I., Nagy J. Prevalence, course and risk factors of diabetic nephropathy in type-2 diabetes mellitus. Med. Sci. Monit. 2000;6(5):929–936. [PubMed] [Google Scholar]
  • 49.Naidoo D.P. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc. J. S. Afr. 2002;13(4):194–199. [PubMed] [Google Scholar]
  • 50.Chen L., Jia R.H., Qiu C.J., Ding G. Hyperglycemia inhibits the uptake of dehydroascorbate in tubular epithelial cell. Am. J. Nephrol. 2005;25(5):459–465. doi: 10.1159/000087853. [DOI] [PubMed] [Google Scholar]
  • 51.Beisswenger P.J., Drummond K.S., Nelson R.G., Howell S.K., Szwergold B.S., Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes. 2005;54(11):3274–3281. doi: 10.2337/diabetes.54.11.3274. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES